Related Experiment Video
Updated: Mar 17, 2026
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Two-year prognosis of admission hemoglobin A1c following a primary percutaneous coronary intervention
1Department of Cardiology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
Insights
Hemoglobin A1c (HbA1c) levels predict outcomes in ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI). Higher HbA1c is linked to increased mortality and adverse cardiovascular events.
Area of Science:
- Cardiology
- Endocrinology
- Clinical Medicine
Background:
- Hemoglobin A1c (HbA1c) is recognized for its diagnostic and predictive value in acute myocardial infarction.
- Assessing the prognostic significance of HbA1c in STEMI patients is crucial for risk stratification.
Purpose of the Study:
- To evaluate the impact of HbA1c levels on patient outcomes following primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
- To determine the short-term and long-term prognostic role of HbA1c in STEMI patients.
Main Methods:
- Prospective enrollment of 796 STEMI patients undergoing primary PCI between December 2013 and June 2015.
- Classification of patients into three groups based on admission HbA1c levels: ≤5.6%, 5.7-6.4%, and ≥6.5%.
- Follow-up for in-hospital and 2-year cardiovascular (CV) mortality and morbidity.
Main Results:
- A significant association was observed between HbA1c levels and 2-year primary clinical outcomes.
- Elevated HbA1c levels correlated with increased CV mortality, heart failure/shock, and major adverse cardiovascular events (P<0.001).
Conclusions:
- Hemoglobin A1c is an independent predictor of in-hospital and long-term mortality in STEMI patients treated with primary PCI.
- HbA1c independently predicts nonfatal reinfarction and target vessel revascularization in this patient cohort.
Objective:
We sought to assess the effect of hemoglobin A1c (HbA1c) on the outcomes of a primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).
Background:
Many studies have shown the diagnostic and predictive value of HbA1c levels in patients with acute myocardial infarction. We assessed the prognostic role of HbA1c in short-term and long-term mortality in 796 consecutive patients with STEMI.
Methods And Results:
A total of 796 patients with STEMI undergoing primary PCI were prospectively enrolled between December 2013 and June 2015. The patients were divided into three groups on the basis of admission HbA1c levels: group I (HbA1c≤5.6%), group II (HbA1c 5.7-6.4%), and group III (HbA1c≥6.5%). The in-hospital and 2-year cardiovascular (CV) mortality and morbidity of all three patient groups were followed up. A significant association was found between HbA1c level and 2-year primary clinical outcomes, including CV mortality, heart failure/shock, and major adverse cardiovascular event (P<0.001).
Conclusion:
HbA1c is an independent predictor of the in-hospital and long-term mortality, nonfatal reinfarction, and target vessel revascularization in STEMI patients treated with primary PCI.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Cardiac Catheterization I: Pre-Procedure Overview